[Pharmacotherapeutical perspectives in Alzheimer's disease].
Martínez-Lage
J M
JM
Departamento de Neurología y Neurocirugía, Universidad de Navarra, Pamplona, España.
D000110:Acetylcholinesterase / Q000378:metabolism; D000375:Aging; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology; D016229:Amyloid beta-Peptides; D001921:Brain / Q000201:enzymology / Q000473:pathology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D018846:Excitatory Amino Acids; D006801:Humans; D007249:Inflammation / Q000473:pathology; D018384:Oxidative Stress; D011976:Receptors, Muscarinic / Q000187:drug effects; D011978:Receptors, Nicotinic / Q000187:drug effects
D016229:Amyloid beta-Peptides; D002121:Calcium Channel Blockers; D018680:Cholinergic Antagonists; D018846:Excitatory Amino Acids; D011976:Receptors, Muscarinic; D011978:Receptors, Nicotinic; D000110:Acetylcholinesterase